TTR and cardiac amyloidosis: <h4>Objectives</h4>To identify unique echocardiographic signatures associated with <i>TTR</i>+ carrier status preceding onset of cardiac amyloidosis.<h4>Background</h4>Carrier status for the most common pathogenic <i>TTR</i> variant in the United States, Val142Ile (V142I), found in 4% of African Americans (AA) and 1% of Hispanic/Latino (H/L) individuals, confers a 40-60% lifetime risk of developing variant transthyretin amyloidosis (ATTRv), including cardiac amyloidosis (CA) and heart failure (HF).